Evidence map›Paper›PMID 41445846›Full record

ArticleCancer management and research2025

Baicalein Inhibits Proliferation, Migration, and Invasion of Mesothelioma Cells Through the p53-FOXM1 Signaling Axis.

Xin-Yi Zheng, Chao Guo, Jie Peng, Ping-Xiang Tang, Ze Xia, Wen-Fei Xu, Xu-Hui Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xin-Yi Zheng *College of Fisheries and Life Science, Shanghai Ocean University, Shanghai, People's Republic of China.ORCID 0000-0001-9308-428X
Chao Guo *Zhejiang Key Laboratory of Multiomics and Molecular Enzymology, Yangtze Delta Region Institute of Tsinghua University, Zhejiang, Jiaxing, Zhejiang, 314006, People's Republic of China.
Jie Peng *Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.
Ping-Xiang TangCollege of Fisheries and Life Science, Shanghai Ocean University, Shanghai, People's Republic of China.
Ze XiaZhejiang Key Laboratory of Multiomics and Molecular Enzymology, Yangtze Delta Region Institute of Tsinghua University, Zhejiang, Jiaxing, Zhejiang, 314006, People's Republic of China.
Wen-Fei XuZhejiang Key Laboratory of Multiomics and Molecular Enzymology, Yangtze Delta Region Institute of Tsinghua University, Zhejiang, Jiaxing, Zhejiang, 314006, People's Republic of China.
Xu-Hui LiCollege of Fisheries and Life Science, Shanghai Ocean University, Shanghai, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Baicalein, a natural flavonoid derived from the root of Materials and Methods: Effects of baicalein on mesothelioma cells phenotypic changes were investigated by measuring cell proliferation, apoptosis, migration, invasion, and cell-cycle alterations. Bioinformatic methods were applied to predict the mechanisms by which baicalien mediated its antitumor roles in mesothelioma. Crucial signaling molecules among p53-FOXM1 signaling axis, including p53, FOXM1 and cyclin B1, were evaluated by immunoblotting in mesothelioma cells. Results: Treatment with baicalein significantly inhibited mesothelioma cell viability in a dose-dependent manner, with 48 h IC Conclusion: Baicalein suppresses mesothelioma cell growth and invasion in vitro through modulation of the p53-FOXM1 signaling axis. These findings support its potential as a lead compound for further preclinical evaluation in mesothelioma.

Indexed as

antitumor activityBaicaleinFOXM1mesotheliomap53traditional Chinese medicine

Identifiers

PMID41445846
PMCPMC12723259

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.